Obesity Surgery

, Volume 19, Issue 3, pp 313–320 | Cite as

GLP-1 and Adiponectin: Effect of Weight Loss After Dietary Restriction and Gastric Bypass in Morbidly Obese Patients with Normal and Abnormal Glucose Metabolism

  • Camila Puzzi de Carvalho
  • Daniela Miguel Marin
  • Aglécio Luiz de Souza
  • José Carlos Pareja
  • Elintom Adami Chaim
  • Silvia de Barros Mazon
  • Conceição Aparecida da Silva
  • Bruno Geloneze
  • Elza Muscelli
  • Sarah Monte AlegreEmail author
Research Article



It has been proposed that there is improvement in glucose and insulin metabolism after weight loss in patients who underwent diet restriction and bariatric surgery.


Eleven normal glucose tolerant (NGT) morbidly obese patients [body mass index (BMI), 46.1 ± 2.27 g/m2] and eight abnormal glucose metabolism (AGM) obese patients (BMI, 51.20 kg/m2) were submitted to diet-restriction and bariatric surgery. Prospective study on weight loss changes, over the glucose, insulin metabolism, glucagon-like peptide-1 (GLP-1), and adiponectin levels were evaluated by oral glucose tolerance test during three periods: T1 (first evaluation), T2 (pre-surgery), and T3 (9 months after surgery).


Insulin levels improved after surgery. T1 was 131.1 ± 17.60 pmol/l in the NGT group and 197.57 ± 57.94 pmol/l in the AGM group, and T3 was 72.48 ± 3.67 pmol/l in the NGT group and 61.2 ± 9.33 pmol/l in the AGM group. The major reduction was at the first hour of the glucose load as well as fasting levels. At 9 months after surgery (T3), GLP-1 levels at 30 and 60 min had significantly increased in both groups. It was observed that the AGM group had higher levels of GLP-1 at 30 min (34.06 ± 6.18 pmol/l) when compared to the NGT group (22.69 ± 4.04 pmol/l). Homeostasis model assessment of insulin resistance from the NGT and AGM groups had a significant reduction at periods T3 in relation to T1 and T2. Adiponectin levels had increased concentration in both groups before and after surgical weight loss. However, it did not have any statistical difference between periods T1 vs. T2.


Weight loss by surgery leads to improvement in the metabolism of carbohydrates in relation to sensitivity to the insulin, contributing to the reduction of type 2 diabetes incidence. This improvement also was expressed by the improvement of the levels of adiponectin and GLP-1.


GLP-1 Adiponectin Morbid obesity Gastric bypass surgery Glucose metabolism disorders Insulin resistance 



We thank all who contributed to this project. Financial support was by Fundação de Amparo à Pesquisa (FAPESP; SP, Brasil).


  1. 1.
    Bonadonna RC, Groop L, Kraemer N, et al. Obesity and insulin resistance in humans: a dose-response study. Metabolism 1990;39:452–9.CrossRefGoogle Scholar
  2. 2.
    Defronzo RA, Bonadonna RA, Ferranini E. A balanced overview. Diabetes Care. 1990;15:318–68.CrossRefGoogle Scholar
  3. 3.
    Hostamisligil GS. Molecular mechanisms of insulin resistance and the role of adipocyte. Int J Obes. 2000;24:S23–7.CrossRefGoogle Scholar
  4. 4.
    Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associate risk factor finding in the US population from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2003;163:427–36.CrossRefGoogle Scholar
  5. 5.
    Colditz G, Willet W, Rotniztky A, et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol. 1990;132:501–13.CrossRefGoogle Scholar
  6. 6.
    Pories WJ, Macdonald KG Jr, Morgan EJ, et al. Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. Am J Clin Nutr. 1992;55:582S–5.CrossRefGoogle Scholar
  7. 7.
    Residori L, Garcia-Lorda P, Flancbaum L, et al. Prevalence of co-morbidities in obese patients before bariatric surgery: effect of race. Obes Surg. 2003;13:333–40.CrossRefGoogle Scholar
  8. 8.
    Buchwald H, Avidor Y, Brawnwald E, et al. Bariatric surgery: a systemic review and meta-analysis. JAMA 2004;2992:1724–37.CrossRefGoogle Scholar
  9. 9.
    Blandine L, Stanley H, Krystle W, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007;30:1709–16.CrossRefGoogle Scholar
  10. 10.
    MacDonald PE, El-kholy W, Riedel MJ, et al. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002;51:S434–42.CrossRefGoogle Scholar
  11. 11.
    Creutzfedt W. The entero-insulinar axis in type 2 diabetes. Incretins as therapeutic agents. Exp Clin Endocrinol Diabetes. 2001;109:S288–303.CrossRefGoogle Scholar
  12. 12.
    Egan JM, Meneilly GS, Haberner JF, et al. Glucagon-like peptide augments insulin-mediated glucose uptake in obese state. J Clin Endocrinol Metab. 2002;87:3768–73.CrossRefGoogle Scholar
  13. 13.
    Valverde I, Villanueva-Penacarrillo ML, Malaisse WJ. Pancreatic and extrapancreatic effects of GLP-1. Diabetes Metab. 2002;28:3S85–9.PubMedGoogle Scholar
  14. 14.
    Villanueva-Penacarrillo ML, Puente J, Redondo A, et al. Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in NDDM and IDDM rats. Endocrine 2001;15:241–8.CrossRefGoogle Scholar
  15. 15.
    Acitores A, Gonzáles N, Sancho V, et al. Participation of protein kinases in the stimulant action of GLP-1 upon 2-deoxy-D-glucose uptake by normal rat skeletal muscle. Horm Metab Res. 2005;37:275–80.CrossRefGoogle Scholar
  16. 16.
    Sancho V, Trigo MV, González N, et al. Effects of GLP-1 and exendins on kinase activity, 2-deoxy-D-glucose transport, lipolysis and lipogenesis in adipocytes from normal and streptozotocin-induced type 2 diabetic rats. J Mol Endocrinol. 2005;35:27–38.CrossRefGoogle Scholar
  17. 17.
    Ruiz-Grande C, Alarcón C, Mérida E, et al. Lipolytic action of glucagon-like peptides in isolated rat adipocytes. Peptides 1992;13:13–6.CrossRefGoogle Scholar
  18. 18.
    Perea A, Vinambres C, Clement F, et al. GLP-1 (7–36) amide effects on glucose transport and metabolism in rat adipose tissue. Horm Metab Res. 1997;9:417–21.CrossRefGoogle Scholar
  19. 19.
    Villanueva-Penacarrillo ML, Márquez L, González N, et al. Effect of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res. 2001;33:73–7.CrossRefGoogle Scholar
  20. 20.
    Nauck A, Heinesaat MM, Orskov C, et al. Preserved incretin activity of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes. J Clin Invest. 1993;91:301–7.CrossRefGoogle Scholar
  21. 21.
    Blandine L, Stanley H, Krystle W, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007;30:1709–16.CrossRefGoogle Scholar
  22. 22.
    Maeda K, Okubo K, Simomura J, et al. c-DNA cloning and expression of a novel adipose-specific collagen-like factor, ap M1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun. 1996;221:286–9.CrossRefGoogle Scholar
  23. 23.
    Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270:26746–9.CrossRefGoogle Scholar
  24. 24.
    Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996;18:10697–730.CrossRefGoogle Scholar
  25. 25.
    Takahashi M, Arita Y, Yamagata K, et al. Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes. 2000;24:861–8.CrossRefGoogle Scholar
  26. 26.
    Okamoto Y, Arita Y Nishida M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res. 2000;32:47–50.CrossRefGoogle Scholar
  27. 27.
    Ouchi N, Kihara S, Arita T, et al. Novel modulator of endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473–6.CrossRefGoogle Scholar
  28. 28.
    Ouchi N, Kihara S, Arita T, et al. Adiponectin, and adipocyte-derived plasma protein, inhibits NF-kb signaling through a cAMP-dependent pathway. Circulation 2000;102:1296–301.CrossRefGoogle Scholar
  29. 29.
    Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the function of macrophages. Blood 2000;96:1723–32.Google Scholar
  30. 30.
    Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930–5.CrossRefGoogle Scholar
  31. 31.
    Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory, adiponectin. J Clin Endocrinol Metab. 2001;86:3815–9.CrossRefGoogle Scholar
  32. 32.
    Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose–specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595–9.CrossRefGoogle Scholar
  33. 33.
    Stefan N, Vozarova B, Funahashi T, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitvity in humans. Diabetes 2002;51:1884–8.CrossRefGoogle Scholar
  34. 34.
    National Institutes of Health. The Seventh Report of Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII). NIH Publication no. 03-5233. EUA, 2003; p. 2–3.Google Scholar
  35. 35.
    Fobi MAL, Lee H, Igwe D, et al. Revision on failed gastric bypass to distal Roux-en-Y gastric bypass: a review of 65 cases. Obes Surg. 2001;11:190–5.CrossRefGoogle Scholar
  36. 36.
    Fulcher GR, Farrer M, Walker M, et al. A comparison of measurements of lean body mass derived by bioelectrical impedance, skinfold thickness and total body potassium. A study in obese and non-obese normal subjects. Scand J Lab Invest. 1991;51:245–53.CrossRefGoogle Scholar
  37. 37.
    American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Clinical practice recommendations 2003: committee report. The expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26(1):S4–20.Google Scholar
  38. 38.
    Potteiger JA, Jacobsen DJ, Donnelly JE. A comparison of methods for analyzing glucose and insulin areas under the curve following nine months of exercise in overweight adults. Int J Obes. 2002;26:87–9.CrossRefGoogle Scholar
  39. 39.
    Mcauley KA, Williams SM, Mann JI, et al. Diagnosing insulin resistance in the general population. Diabetes Care. 2001;24:460–4.CrossRefGoogle Scholar
  40. 40.
    Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment, insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–9.CrossRefGoogle Scholar
  41. 41.
    Sjostrom CD, Peltonem M, Wedel H, et al. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000;36:20–5.CrossRefGoogle Scholar
  42. 42.
    Marin, D. Resistência à insulina e função da célula beta: Efeito da perda de peso após bypass gástrico. PhD Thesis, Universidade Estadual de Campinas. Faculdade de Ciências Médicas; 2007.Google Scholar
  43. 43.
    Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive Substances. Ann NY Acad Sci. 1999;892:146–54.CrossRefGoogle Scholar
  44. 44.
    Tomas E, Tsao TS, Saha AK, et al. Enhanced muscle fat oxidation and glucose transport by ACRP 30 globular domain: a domain: acetyl- CoaA carboxylase inhibition and AMP- activated protein kinase activation. Proc Natl Acad Sci USA. 2002;99:16309–13.CrossRefGoogle Scholar
  45. 45.
    Yamauchi T, Kamon J, Minokashi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288–95.CrossRefGoogle Scholar
  46. 46.
    Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and function of the macrofages. Blood 2000;96:1723–32.Google Scholar
  47. 47.
    Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930–5.CrossRefGoogle Scholar
  48. 48.
    Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA. 2001;98:2005–10.CrossRefGoogle Scholar
  49. 49.
    Host JJ. On the physiology of GIP and GLP-1. Horm Metab Res. 2004;34:747–54.CrossRefGoogle Scholar
  50. 50.
    Vilsboll T, Host JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 2004;47:357–66.CrossRefGoogle Scholar
  51. 51.
    Greenway SE, Greenway F, Klein S. Effects of obesity surgery on non-insulin-dependent diabetes mellitus. Arch Surg. 2002;137:1109–77.CrossRefGoogle Scholar
  52. 52.
    Drucker DJ. Glucagon-like peptide-1 and the islet ß-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 2003;144:5145–8.CrossRefGoogle Scholar
  53. 53.
    Zander M, Masdbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycemic control, insulin sensitivity, and ß-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824–30.CrossRefGoogle Scholar
  54. 54.
    Drucker DJ. Enhancing incretin action for treatment of type 2 diabetes. Diabetes Care. 2003;26:2929–40.CrossRefGoogle Scholar
  55. 55.
    Cummings DA, Overduin J, Fosyrt-Schubert K. Gastric bypass for obesity: mechanism of weight loss and diabetes resolution. J Clin Encrinol Metab. 2004;89:2608–15.CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • Camila Puzzi de Carvalho
    • 1
  • Daniela Miguel Marin
    • 1
  • Aglécio Luiz de Souza
    • 1
  • José Carlos Pareja
    • 2
  • Elintom Adami Chaim
    • 2
  • Silvia de Barros Mazon
    • 3
  • Conceição Aparecida da Silva
    • 1
  • Bruno Geloneze
    • 1
  • Elza Muscelli
    • 1
  • Sarah Monte Alegre
    • 1
    • 4
    Email author
  1. 1.Department of Internal Medicine, Faculdade de Ciências MédicasUniversidade Estadual de CampinasSão PauloBrazil
  2. 2.Surgery Department, Faculdade de Ciências MédicasUniversidade Estadual de CampinasSão PauloBrazil
  3. 3.Department of Clinic Pathology, Faculdade de Ciências MédicasUniversidade Estadual de CampinasSão PauloBrazil
  4. 4.Department of Internal Medicine, Faculty of Medical SciencesUniversity of Campinas (UNICAMP)CampinasBrazil

Personalised recommendations